• Explore /
  • Poster
  • / Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Abstract Poster

Authors

null

Masatoshi Kudo

Kindai University Faculty of Medicine, Osaka, Osaka, Japan

Masatoshi Kudo , Richard S. Finn , Tim Meyer , Frederic Boisserie , Songzi Li , Yaxi Chen , Ramil Abdrashitov , Andrew X. Zhu , Arndt Vogel , Shukui Qin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03412773

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4083)

DOI

10.1200/JCO.2023.41.16_suppl.4083

Abstract #

4083

Poster Bd #

404

Abstract Disclosures

Similar Posters

First Author: Arndt Vogel

First Author: Richard S. Finn

First Author: Richard S. Finn

First Author: David Edward Kaplan